Guangzhou Center for Disease Control and Prevention; Guangzhou, PR China.
Hum Vaccin Immunother. 2013 Dec;9(12):2524-8. doi: 10.4161/hv.26113. Epub 2013 Aug 16.
Although mumps-containing vaccines were introduced in China in 1990s, mumps continues to be a public health concern due to the lack of decline in reported mumps cases. To assess the mumps vaccine effectiveness (VE) in Guangzhou, China, we performed a 1:1 matched case-control study. Among children in Guangzhou aged 8 mo to 12 y during 2006 to 2012, we matched one healthy child to each child with clinically diagnosed mumps. Cases with clinically diagnosed mumps were identified from surveillance sites system and healthy controls were randomly sampled from the Children's Expanded Programmed Immunization Administrative Computerized System in Guangzhou. Conditional logistic regression was used to calculate VE. We analyzed the vaccination information for 1983 mumps case subjects and 1983 matched controls and found that the overall VE for 1 dose of mumps vaccine, irrespective of the manufacture, was 53.6% (95% confidence interval [CI], 41.0-63.5%) to children aged 8 mo to 12 y. This post-marketing mumps VE study found that immunization with one dose of the mumps vaccine confers partial protection against mumps disease. Evaluation of the VE for the current mumps vaccines, introduction of a second dose of mumps vaccine, and assessment of modifications to childhood immunization schedules is essential.
尽管中国在 20 世纪 90 年代引入了含有腮腺炎病毒的疫苗,但由于报告的腮腺炎病例并未减少,腮腺炎仍然是一个公共卫生关注的问题。为了评估中国广州的腮腺炎疫苗效力(VE),我们进行了 1:1 匹配的病例对照研究。在 2006 年至 2012 年期间,广州 8 个月至 12 岁的儿童中,我们将每例临床诊断为腮腺炎的儿童与 1 名健康儿童进行匹配。通过监测点系统确定临床诊断为腮腺炎的病例,而健康对照则从广州儿童扩展计划免疫管理计算机系统中随机抽取。使用条件逻辑回归计算 VE。我们分析了 1983 例腮腺炎病例和 1983 例匹配对照的接种信息,发现无论制造商如何,1 剂腮腺炎疫苗对 8 个月至 12 岁儿童的总体 VE 为 53.6%(95%置信区间[CI],41.0-63.5%)。这项上市后腮腺炎 VE 研究发现,接种 1 剂腮腺炎疫苗可对腮腺炎疾病提供部分保护。评估当前腮腺炎疫苗的 VE、引入第二剂腮腺炎疫苗以及评估儿童免疫接种计划的修改至关重要。